Clinical application of combined anticoagulation therapy in anti-MDA5 antibody-positive associated interstitial lung disease-a retrospective study
Combined anticoagulation therapy improves pulmonary function, reduces inflammation, and lowers complication and exacerbation risks in anti-MDA5 antibody-positive interstitial lung disease patients. With notable clinical value, it offers a new treatment strategy for this refractory disease.
Authors
- Dongmei Zhou (ORCID: https://orcid.org/0000-0002-7917-7954)
- Ting Zhang (ORCID: https://orcid.org/0000-0002-2274-6677)
- Hua Ma (ORCID: https://orcid.org/0000-0002-2403-1376)
- Lu Li (ORCID: https://orcid.org/0000-0003-1643-1684)
- Lina Cao
- Hai Tang (ORCID: https://orcid.org/0000-0002-7344-6041)
- Yuanyuan Song (ORCID: https://orcid.org/0000-0001-5289-3777)
Institutions
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fphar.2025.1662306
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00